Sanofi Canada is very pleased to announce that Quebec has extended its listing of DUPIXENT® (dupilumab injection) under the Régie de l'assurance maladie du Québec (RAMQ) to include public reimbursement for Canadians aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The specific criteria for reimbursement are available on the RAMQ website.
DUPIXENT® (dupilumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate-to-severe atopic dermatitis yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.